Clinical analysis of antiviral effects of entecavir in patients with chronic hepatitis B

Objective To study the antiviral effects of entecavir in patients with chronic Hepatitis B.Methods Thirty-seven patients with no prior history of antiviral therapy were divided randomizely into two groups:entecavir group(18 cases),and lamivudine group(19 cases).The dosage in the entecavir group and lamivudine group was 0.5 mg/d and 100 mg/d,respectively,and the duration of therapy was 48～96 weeks.The effects of entecavir and lamivudin on HBV DNA,ALT,HBeAg/HBeAb seroconversion and their adverse reactions were observed during the treatment.Results The patients with undetectable serum levels of HBV DNA in the entecavir group were more than those in the lamivudine group,that is,55.56% versus 31.58% on week 24,and 83.33% versus 36.84% on week 48 after treatment.There were no marked differences in the HBeAg negative conversion rate,HBeAg/HBeAb seroconverse rate,and the incidence of adverse reactions between the two groups.Conclusion Entecavir is more effective in inhibiting reproduction of HBV than that of lamivudine,and entecavir is similar to lamivudine in the incidence of adverse reactions.